Radiotherapy related prognostic factors in brain metastasis patients who have undergone whole brain radiotherapy or with local boost and survived more than 6 months

Kızıltan H., ÇOBAN G., Altınok P., TEKÇE E., MAYADAĞLI A.

International Journal of Radiation Research, vol.21, no.1, pp.37-44, 2023 (Scopus) identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 1
  • Publication Date: 2023
  • Doi Number: 10.52547/ijrr.21.1.5
  • Journal Name: International Journal of Radiation Research
  • Journal Indexes: Scopus
  • Page Numbers: pp.37-44
  • Keywords: SRS, SBRT, Simultaneous, Integrated Boost, brain metastasis, TomoTherapy, radiotherapy
  • Bezmialem Vakıf University Affiliated: Yes


Background: In this study, prognostic features of radiation were investigated in cancer patients with 1-10 brain metastases (BM) who have not under surgery and survived longer than 6 months. Materials and Methods: This retrospective study included 136 patients have lung, breast, colon cancer and malign melanoma (MM) with 1-10 BM. All patients and data of BM patients who lived longer than 6 months radiotherapy (RT) related factors affecting their survival rates were examined. Patients were given only WBRT (Whole brain Radiotherapy) in 8-20 fractions with a 160-300 cGy / day fraction, or WBRT with local boost RT with an additional daily 300-350 cGy fraction. Results: When the results were evaluated analysis showed that the having CT, breast cancer, a KPS of 60% or more, daily fraction dose of RT affected survival significantly in all patients. Then subgroub analysis were obtained according to survival rates, number of metastases more than 5 affects life negatively (r=-0.435 and p=0.03) for survival longer than 6 months (SL6m) and survival shorter or equal than 6 months SS6m. The WBRT doses of 3000 cGy with 300 cGy daily fraction size negatively affected life compared to 2500 cGy with 250 cGy (r=-0.280 and p=0.01). Conclusion: It was determined that KPS > 60 and limiting WBRT doses up to 250 / 2500 cGy daily and total in patients with BM between 1-10 was the important best prognostic factor due to RT for SL6m, which increased patient performance and survival rates.